Stocks Health care VRTX
NASDAQ · Health careVertex Pharmaceuticals Inc / MA (VRTX)
Vertex Pharmaceuticals Inc / MA brought in $12.6B of revenue over the twelve months to June 30, 2026, up 10.2% from a year earlier. Net income was $4.4B, a net margin of 35.0%. Operating cash flow minus capital spending left $3.2B of free cash flow in fiscal 2025. At June 30, 2026 it held $6.1B in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Vertex Pharmaceuticals Inc / MA does
Vertex Pharmaceuticals develops and commercializes small molecule drugs and gene therapies. The company is best known for developing cystic fibrosis treatments, including Trikafta and Kalydeco. Its therapies are prescribed to patients and sold through specialty pharmacies and distributors. Its shares trade on NASDAQ under the ticker VRTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $12B | $4B | $15.32 | $3.2B |
| 2024 | $11B | -$535.6M | -$2.08 | -$790.3M |
| 2023 | $9.9B | $3.6B | $13.89 | $3.3B |
| 2022 | $8.9B | $3.3B | $12.82 | $3.9B |
| 2021 | $7.6B | $2.3B | $9.01 | $2.4B |
| 2020 | $6.2B | $2.7B | $10.29 | $3B |
Latest SEC filings
What Vertex Pharmaceuticals Inc / MA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- July 7, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Form S-8 POS filing S-8 POS
- May 13, 2026Form S-8 POS filing S-8 POS
- May 13, 2026Form S-8 POS filing S-8 POS
- May 13, 2026Form S-8 POS filing S-8 POS
Questions about VRTX
What does Vertex Pharmaceuticals Inc / MA do?
Vertex Pharmaceuticals develops and commercializes small molecule drugs and gene therapies. The company is best known for developing cystic fibrosis treatments, including Trikafta and Kalydeco. Its therapies are prescribed to patients and sold through specialty pharmacies and distributors. Its shares trade on NASDAQ under the ticker VRTX.
Is Vertex Pharmaceuticals Inc / MA profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $4.4B on revenue of $12.6B, a net margin of 35.0%.
How much revenue does Vertex Pharmaceuticals Inc / MA make?
Over the twelve months to June 30, 2026 Vertex Pharmaceuticals Inc / MA reported revenue of $12.6B. That is 10.2% more than a year earlier.
When did Vertex Pharmaceuticals Inc / MA last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Follow VRTX
Get an email when Vertex Pharmaceuticals Inc / MA files with the SEC: results, executive changes, material agreements and annual reports.
Follow VRTX: get an email when it filesWhere the numbers come from
Financial figures are the values Vertex Pharmaceuticals Inc / MA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.